Actelion Pharmaceuticals Ltd : Actelion's Annual General Meeting of
Shareholders held in Basel, Switzerland
Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of
Shareholders held in Basel, Switzerland . Processed and transmitted by Thomson
Reuters ONE. The issuer is solely responsible for the content of this
ALLSCHWIL/BASEL, SWITZERLAND - 18 April 2013 - At today's Annual General
Meeting of Actelion Ltd (SIX: ATLN), held in Basel Switzerland, shareholders
voted on a number of resolutions put forward by the Company's Board.
The meeting was attended by 272 shareholders. A total of 60'550'649 shares or
47.76% of the total outstanding shares were represented.
Lead by the Chairman of the Board, Jean-Pierre Garnier, the company presented
a review of the company's 2012 performance. Highlights included the ongoing
demand for Actelion's medicines, the success in key clinical studies, the
strategic refocusing on specialty pharmaceuticals and the continuation of an
800 million share buyback program. The chairman reminded the shareholders that
Actelion created significant value in the year under review and was among the
top performers in the 2012 Blue Chip Index SMI at the Swiss Stock Market.
The shareholders approved the Business Report consisting of the Annual Report,
the Annual Statutory Accounts and the Consolidated Accounts for the year 2012.
A proposal by the Board to appropriate available earnings from capital
contribution and distribute as a dividend in the amount of CHF 1.00 per
registered share was passed by shareholders.
Shareholders did not vote favorably in the consultative vote on the 2012
compensation report, with 60.24 percent against. The Chairman of the Board
expressed his confidence that - based on the changes already made for 2013 and
through ongoing consultation with shareholders - a remuneration system will be
put in place that will find the approval of the company's owners at the next
The shareholders granted discharge to all members of the Board of Directors
and of the Senior Management.
A proposal by the Board to reduce share capital by cancellation of repurchased
shares was passed by the shareholders.
Actelion's shareholders re-elected Mr. Werner Henrich, Mr. Armin Kessler and
Mr. Jean Malo to the Board for a term of three years.
In addition, the shareholders elected a new director, Mr. John J. Greisch, to
the Board for a term of three years.
Following the AGM, Actelion's Board comprises a total of eleven members:
Jean-Pierre Garnier (Chairman), Juhani Anttila, Robert Bertolini, Jean-Paul
Clozel, Carl Feldbaum, John J. Greisch, Peter Gruss, Werner Henrich, Michael
Jacobi, Armin Kessler and Jean Malo.
Finally, the shareholders confirmed Ernst & Young as the Company's statutory
auditors for the business year 2013.
NOTES TO THE EDITOR
ABOUT MR JOHN J. GREISCH
Mr. John J. Greisch is currently President (as Executive Director) and Chief
Executive Officer of Hill-Rom Holdings, Inc., a leading medical supplier of
patient support systems such as hospital beds, therapeutic surfaces and
stretchers. Under Mr. Greisch's leadership, Hill-Rom increased its investments
in research and development, introducing new smart bed technology and new
surfaces to the market as well as expanding its Singapore-based Asia-Pacific
Before joining Hill-Rom, Mr. Greisch spent seven years at Baxter
International, Inc. in various executive positions in corporate finance,
operations and general management. From 2004-2006, he served as Chief
Financial Officer and from 2006-2009 as President International Operations.
Mr Greisch earned a Bachelor's degree in Business Administration from the
Miami University, US and a Master's Degree in Management (MBA equivalent) from
the Northwestern University in Illinois, US
Mr. Greisch also serves on the Board of Lurie Children's Hospital in Chicago
and is a past member of the Business School Advisory Board for Miami
University's Farmer School of Business.
ABOUT ACTELION LTD.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its
own subsidiaries in key markets worldwide, including the United States (based
in South San Francisco), the European Union, Japan, Canada, Australia and
Founded in late 1997 Actelion is a leading player in innovative science
related to the endothelium - the single layer of cells separating every blood
vessel from the blood stream. Actelion's over 2,400 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
For further information please contact:
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
Press Release PDF
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
Press spacebar to pause and continue. Press esc to stop.